Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Aro Biotherapeutics
company
About
Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $88M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$88M
Aro Biotherapeutics has raised a total of
$88M
in funding over 2 rounds. Their latest funding was raised on
Jan 5, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 5, 2021 | Series A | $88M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Aro Biotherapeutics is funded by 1 investors.
Ionis Pharmaceuticals
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Ionis Pharmaceuticals
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
